Retrospective Analysis of Drug Sensitivity of Neisseria gonorrhoeae in Teaching Hospitals of South China

Introduction

Neisseria gonorrhoeae infection, one of the most common sexually transmitted disease, is a global problem.¹ In mainland china, the incidence of N. gonorrhoeae infection has increased continuously, with the incidence rate among the top five of national notifiable infectious diseases.² A wide spectrum of clinical manifestations and complications of N. gonorrhoeae infection has been observed, and the vaccine against N. gonorrhoeae is not available at present. Therefore, the infection control predominantly relies on timely diagnosis and appropriate antibiotic therapy.^1–4 Over time, Neisseria gonorrhoeae has developed resistance to a broad range of antimicrobial agents. Some sensitive antibiotics, such as ceftriaxone, have been reported to have become ineffective in the recent years.^5,6 The rapid development of N. gonorrhoeae resistance to antimicrobial agents worldwide will threaten the management of N. gonorrhoeae infection.¹

This study is a retrospective analysis of drug sensitivity of Neisseria gonorrhoeae in the two teaching hospitals of South China from 2016 to 2020.

Materials and Methods

Retrospective analysis of drug sensitivity of Neisseria gonorrhoeae in two teaching hospitals of Guangzhou, South China from 2016 to 2020 was performed.

The demographic and clinical information of patients such as gender, age, and symptoms was collected using electronic case system. Each isolate was cultured and verified.⁷ MIC for penicillin, cefuroxime, ceftriaxone (CRO), cefepime, ciprofloxacin, ceftazidime and azithromycin (AZM) were determined by the agar dilution method. Antimicrobial susceptibility was interpreted according to criteria defined by WHO.^8,9

The β-lactamase was detected by enzyme linked immunosorbent assay (ELISA).¹⁰ Ureaplasma urealyticum and Mycoplasma hominis was determined by culture in liquid medium, and Chlamydia was detected by rapid antigen test.¹⁰ All the results were collected using electronic case system and clinical examination electronic system.

Statistical significance was assessed using SPSS 18.0. Chi-square tests were used for statistical analyses. A P < 0.05 was considered to be significant.

Results

Three hundred and four patients with Neisseria gonorrhoeae infection were included in this study. The study included 282 male and 22 females. The age range was from 16 to 75 years, with the average age 30.30±9.11 years. From 2016 to 2020, resistance rate to ceftriaxone was 6.38%, 8.06%, 8.86%, 14.29% and 11.67%, respectively, the average resistance was 9.87%. Resistance to azithromycin was 6.38%, 9.68%, 10.13%, 12.50% and 16.67%, respectively, in 2016 to 2020, and the average resistance was 11.18% (Table 1). The differences in the resistance rate between 2016 and 2020 were statistically significant for ceftriaxone and azithromycin (P < 0.05).

Table 1 Antimicrobial Resistance to Neisseria gonorrhoeae Infection from 2016 to 2020

From 2016 to 2020, β-lactamase positive of Neisseria gonorrhoeae was rising every year (P < 0.05). Neisseria gonorrhoeae infection combined with Chlamydia infection and Ureaplasma urealyticum infection was also increased gradually (P < 0.05) (Table 2).

Table 2 Neisseria gonorrhoeae Infection in Teaching Hospitals from 2016 to 2020

Discussion

The vaccine against N.gonorrhoeae is not available at present; a wide spectrum of clinical manifestations and complications of N. gonorrhoeae infection have increased gradually. Therefore, N.gonorrhoeae infection control predominantly relies on accurate diagnostics and timely antibiotic therapy following antibiotic sensitivity testing.^1–4

In the recent years, the management of N.gonorrhoeae infection has been difficult because of the rapid development of resistance to a broad range of antimicrobial agents.¹

In order to limit the development of antimicrobial resistance and ensure effective treatment, the therapy with ceftriaxone 250 or 500 mg administered intramuscularly plus azithromycin 1 or 2 g orally has been widely accepted as the first choice for the treatment of N. gonorrhoeae infection.¹¹ As the emergence of treatment failure with cephalosporins have been documented in several countries in the 2000s and the warning susceptibility of N. gonorrhoeae, some scholars recommend the use of 1000 mg ceftriaxone intramuscularly.³ In this retrospective study, N. gonorrhoeae resistance rate to ceftriaxone was 6.38%, 8.06%, 8.86%, 14.29% and 11.67%, respectively, from 2016 to 2020. The average resistance was 9.87%. This is consistent with previous studies.^5–7

Situated in Southern China, Guangzhou is the important node city of “the Silk Road” and “The Belt and Road”, which has a large transient population of foreign visitors and business partners. The import and dissemination of antimicrobial resistance is a constant public health threat in Guangzhou. Ceftriaxone-resistant multidrug-resistant N. gonorrhoeae undermines the effectiveness of currently recommended first-line dual therapy. It is imperative to enhanced surveillance of antimicrobial susceptibility, in order to detect and monitor the resistance trends of Neisseria gonorrhoeae, so as to ensure the effectiveness of its treatment.^1,3

In this study, resistance rate from 2016 to 2020 has increased significantly with regard to ceftriaxone and azithromycin. Also, Neisseria gonorrhoeae infection combined with Chlamydia infection and Ureaplasma urealyticum infection has also increased gradually. Pathogenic examination, especially N. gonorrhoeae culture and drug sensitivity test, is more important for the selection of sensitive antibiotics. A limitation of this study is that a small number of cases were assessed.